These studies were done on very small populations, says Erin Palinksi-Wade, R.D., C.D.E., L.D.N
Choi HR, Kang YA, Ryoo SJ, Shin JW, Na JI, Huh CH, et al
Most patients start at 0.25mg per week for the first month
Among these, glucagon-like peptide-1 receptor agonists (GLP1RAs) have attracted particular attention for their profound effects on body weight, glycemic control, and cardiovascular outcomes [4,5] , which extend beyond metabolic effects [4] , alongside emerging evidence of liver-specific benefits [5,6]
This study investigated the pharmacokinetic/pharmacodynamic (PK/PD) properties of a novel concentrated, ultra-rapid-acting formulation of insulin aspart (AT278 U500) in comparison with insulin aspart in the standard concentration (IAsp U100) in overweight and obese people with type 2 diabetes